Plain-English translation of NCT06160843 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications—pembrolizumab and olaparib—to treat peripheral T-cell lymphoma (a rare blood cancer) that has come back or stopped responding to prior treatments. Pembrolizumab works by helping your immune system recognize and fight cancer cells, while olaparib targets cancer cells with specific DNA damage vulnerabilities. The researchers want to see whether giving these two medications together can help patients whose lymphoma has become resistant to other therapies.
Many patients with T-cell lymphoma eventually stop responding to standard treatments, leaving them with few options. This trial exists because early research suggests that combining this medication with another approach might help patients who have reached this difficult point in their disease.
You likely qualify if…
You likely don't qualify if…
You would receive pembrolizumab as an intravenous infusion (through an IV) every 3 weeks, and take olaparib as two tablets by mouth twice daily, every day. Most visits would be on an outpatient basis, meaning you would not need to stay in the hospital. You would be monitored regularly with blood tests and imaging scans to see how your lymphoma responds, and the trial team would watch carefully for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Singapore